Cabenuva
| Chemical Name | cabotegravir/rilpivirine |
| Dosage Form | Injection (intramuscular; 600 mg/3mL, 400 mg/2mL) |
| Drug Class | Antivirals |
| System | Cardiovascular |
| Company | Viiv Healthcare |
| Approval Year | 2021 |
Indication
- Indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.